Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
Live webcasts and 90-day replays of Palvella Therapeutics’ September conference appearances will be available on its website.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Palvella Therapeutics (PVLA) will participate in two healthcare investor conferences in September 2026. CEO and Founder Wes Kaupinen will join a fireside chat at the Cantor Global Healthcare Conference 2026 on September 9, 2026, at 1:35 p.m. ET, and deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 12:00 p.m. ET. Live webcasts and 90-day replays will be accessible via the Events & Presentations section of the company’s website.
Details
News Market Reaction – PVLA
On Sep 2, the day this news came out, PVLA closed 1.58% above the previous close. Our momentum scanner recorded 3 alerts for this stock that day.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- Announcement date
- September 2, 2026
- Article publication
- Cantor conference date
- September 9, 2026
- Cantor Global Healthcare Conference 2026
- Cantor fireside chat time
- 1:35 p.m. ET
- September 9, 2026
- H.C. Wainwright conference date
- September 15, 2026
- H.C. Wainwright 28th Annual Global Investment Conference
- Corporate presentation time
- 12:00 p.m. ET
- September 15, 2026
- Replay availability
- Approximately 90 days
- Following both live events
Historical Context
-
Completed rolling NDA submission for QTORIN rapamycin to the FDA
-
Announced CEO participation in the Canaccord Genuity Growth Conference
-
Reported second-quarter results alongside regulatory and corporate updates
-
Chief Scientific Officer selected to provide public comment at an FDA workshop
-
Scheduled second-quarter financial results and corporate update conference call
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
clinical-stage medical
vascular malformations medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in two upcoming healthcare investor conferences.
Cantor Global Healthcare Conference 2026
Fireside Chat on Wednesday, September 9, 2026, at 1:35 p.m. ET
H.C. Wainwright 28th Annual Global Investment Conference
Corporate Presentation on Tuesday, September 15, 2026, at 12:00 p.m. ET
Live webcasts of the fireside chat and corporate presentation will be available on the Events & Presentations section of Palvella's website at www.palvellatx.com. Archived replays of both webcasts will be available for approximately 90 days following the live events.
About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected timing of the presentation of data from clinical trials, Palvella’s clinical development plans and related anticipated development milestones and anticipated timing of regulatory submissions, Palvella’s expectations with respect to the anticipated FDA review process for the NDA for QTORIN™ rapamycin and potential timing of a commercial launch of QTORIN™ rapamycin, if approved, Palvella’s plans to meet with regulatory authorities, Palvella’s expectations regarding the benefits of breakthrough therapy designation, orphan drug designation and potential benefit of orphan drug exclusivity for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, Palvella’s cash, financial resources and expected runway, Palvella’s expectations regarding its programs, including QTORIN™ rapamycin and QTORIN™ pitavastatin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to make regulatory submissions on anticipated timelines; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORIN™ rapamycin and QTORIN™ pitavastatin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; Palvella’s limited experience in commercial manufacturing; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO
Palvella Therapeutics
wes.kaupinen@palvellatx.com
Media
Marcy Nanus
Vice President of Investor Relations and Corporate Affairs
Palvella Therapeutics
marcy.nanus@palvellatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.